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Abstract
Peto’s paradox is the lack of the expected trend in cancer incidence
as a function of body size and lifespan across species. The leading hy-
pothesis to explain this pattern is natural selection for differential cancer
prevention in larger, longer-lived species. We evaluate whether a similar
effect exists within species, specifically humans. We begin by reanalyzing
a recently published dataset to separate the effects of stem cell number
and replication rate, and show that each has an independent effect on
cancer incidence. When considering the lifetime number of stem cell di-
visions in an extended dataset, and removing cases associated with other
diseases or carcinogens, we find that lifetime cancer incidence per tissue
saturates at approximately 0.3-1.3% for the types considered. We fur-
ther demonstrate that grouping by anatomical site explains most of the
remaining variation. Our results indicate that cancer risk depends not
only on number of stem cell divisions but varies enormously (∼10,000
times) depending on anatomical site. We conclude that variation in risk
of human cancer types is analogous to the paradoxical lack of variation in
cancer incidence among animal species, and may likewise be understood
as a result of evolution by natural selection.
Keywords. cancer, stem cells, carcinogenesis, Peto’s paradox, environ-
ment, disease
Introduction
All else being equal, the probability of obtaining at least a single invasive cancer
over an organism’s lifespan should scale with the number of “targets” – that is,
cell number, cell lifespan, and the number of cell divisions – over a lifetime.
Peto’s paradox is the lack of such a relationship [1], and is good evidence that
over the millions of generations of multicellular evolution, natural selection has
provided species with levels of cancer protection that are proportional to their
body masses and lifespans ([2, 3, 4]; Aktipis et al. [5], this issue). Several
articles in this Special Issue present background and new results on some of
the causes, protection mechanisms and emergent patterns. Far less studied is
∗Corresponding author. Email: michael.hochberg@univ-montp2.fr
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the extent to which this phenomenon, is obtained within a species [6]. That
is, do different cell lineages within an organism show differing levels of cancer
protection based on their relative vulnerabilities (e.g., total stem cell number,
stem cell division rate, mutagenic exposure), and associated cancer mortality
risks for the whole organism? To the extent that cancer is a selective force
on differential resistance between cell lineages, such resistance, being a priori
costly to evolve, may also result in constraints on the evolution of body plans,
an aspect of Peto’s paradox that has rarely been investigated (Boddy et al. [7],
this issue; Kokko and Hochberg [8], this issue).
Here, we use the lens of evolution to reevaluate and reinterpret the data and
results of a recent study by Tomasetti and Vogelstein [9] (hereafter T&V), who
explored possible sources of variation in risk between cancer types. We show
that c. 50% of variation in cancer risk is due to tissue size, indicating that, inde-
pendent of stem cell divisions, larger tissues are more likely to harbour cancers
than smaller tissues. A simpler measure of T&V’s Extra Cancer Risk (a classifi-
cation of cancers most likely to be caused by carcinogens) yields similar findings
to these authors, with some notable differences. Moreover, when using the total
number of stem cell divisions as a metric for cancers that are not typically the re-
sult of disease or carcinogenic exposure, and employing additional data sources,
we find that lifetime cancer incidence per tissue plateaus at approximately 0.3-
1.3% for the cases in an augmented dataset. We further demonstrate that most
of the remaining variation in cancer risk can be explained by grouping cancers
by anatomical site (e.g., pancreas, bone, intestine), and that each site has a
very different risk per stem cell division. Our study indicates new directions
for research in showing how tissue characteristics may independently explain
variation in cancer incidence. We suggest that evolution by natural selection
has occurred on cancer prevention at different anatomical sites in humans as the
underlying driver of overall pattern, analogous to variation in cancer incidence
across species, i.e. Peto’s paradox.
Results
Tomasetti and Vogelstein [9] found a correlation between cancer incidence per
tissue and the lifetime number of stem cell divisions within the tissue for a set of
31 cancer types. They concluded that most of the variation in risk among cancer
types could be explained by random mutations and repair errors during cell
replication. Furthermore, the authors assessed the remaining variation in cancer
risk due to external environment and inherited factors, which they quantified
with an Extra Risk Score (ERS). Cancers with high ERS are indeed known to
be associated with carcinogenic exposure (Fig. 2 in [9]). Below we reinterpret
their results through new statistical analyses and then reanalyse their dataset
with several new additions to assess signatures of natural selection for cancer
prevention.
Independent contributions of division rate and stem cell
number
Tomasetti and Vogelstein calculated the total lifetime number of stem cell divi-
sions (lscd) as s(2+d)−2, where s is the size of the organ’s stem cell population,
2
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and d is the lifetime number of divisions per stem cell. They then tested for a
correlation between lscd and cancer incidence. One way in which their analy-
sis could be extended is to differentiate the individual contributions of s and d
to cancer risk [10, 11]. For instance, a small stem cell population with many
replications (e.g., esophageal cells) may have the same lscd as a large stem cell
population with few replications (e.g., lung cells, see Table S1 in [9]). How-
ever, in the former case, cancer risk may result mainly from replication errors,
while the latter has a considerably larger number of cells potentially exposed to
carcinogenic environments at any point in time.
We conducted a multiple regression analysis with cancer incidence as the
response variable, and log(d+1), log s, and the interaction of log(d+1) and log s
as the explanatory variables. There was no significant correlation between the
two explanatory variables (r = 0.16, n = 31, p > 0.3), indicating that variation
in s is largely independent of variation in d. The multiple regression revealed
significant positive effects of both log s and log(d + 1) on cancer risk (F1,27 >
18, p < 0.0002); the interaction between log s and log(d+ 1) was not significant
(F1,27 = 0.21, p > 0.6). Overall, as expected, the model explained 65% of the
variation in cancer risk, which is identical to the estimate for the composite
lscd in Tomasetti and Vogelstein [9]. To test the effect of stem cell number on
cancer risk, independent of division rate, we first regressed cancer risk on s,
and then performed a partial regression of residual cancer risk on d. The aim
was to remove effects of stem cell number and so obtain the “pure” effect of
division rate. When correcting for effects of s in this way, stem cell division
explains 40% of the variation in risk (Figure 1A). This division rate effect is
weaker than that found by T&V, because our analysis is based on replications
per stem cell rather than over the population of stem cells. Conversely, tissue
stem cell number explains 44% of the variation after correcting for stem cell
division rate (Figure 1B). Figure 1C depicts the combined positive effects of
log(d+1) and log s: cancer risk increases with both increasing stem cell number
and replication in the organ.
Based on our regression model, we propose a simple alternative evaluation
of the replication-independent Extra Cancer Risk (ERS) score. Whereas T&V
calculate the ERS as the product of the logarithms of lifetime risk and total
stem cell replications, we use the residual lifetime risk, describing the difference
between observed and predicted values from the regression (Figure 1C). Like the
ERS, our more intuitive method identifies a subset of cancers that occur more
often than we would expect from the lifetime number of stem cell divisions, in-
cluding most of those that T&V classed as deterministic D-tumours (Figure 2,
blue bars). Of equal importance for understanding possible causation, the resid-
ual lifetime risk also quantifies the extent to which some cancer rates are lower
than expected. Carcinomas of the small intestine, duodenum and pancreas are
more than ten times less frequent than one would predict from the total number
of stem cell divisions (Figure 2, red bars), and these three cancer types appear
as outliers in the residuals distribution and quantile-quantile plots (not shown).
We note that very similar results can be obtained using the residuals from the
regression of risk against lscd, as has been proposed by Tomasetti and Vogel-
stein [12] and Altenberg [10] since the publication of Tomasetti and Vogelstein’s
initial article [9].
3
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The saturation of cancer risk
The above analysis separating the effects of s and d revealed significant, in-
dependent effects of these variables in explaining variation in cancer incidence
in the T&V dataset. The relatively shallow gradients of the linear regression
models present a challenge to the hypothesis that the variation in cancer risk
is largely due to differences in lifetime numbers of stem cell divisions. We next
consider in more detail the shape and interpretation of the relation between the
composite index, lscd, and cancer incidence.
If the risk per cell division were the same for every tissue then
cancer risk = 1− (1− C)lscd (1)
where C is the risk per stem cell division. If C ≪ 1 and cancer risk ≪ 1 (which
holds for alm st all of the T&V data) then this relationship can be re-expressed
(using the binomial approximation) as
cancer risk ≈ C × lscd. (2)
Equivalently,
log(cancer risk) ≈ log(lscd) + log(C), (3)
which means that the slope of the linear regression models should be approxi-
mately 1. Since the gradient of the one-factor linear regression model of T&V
is only 0.53, the risk per stem cell division cannot be the same for all tissues.
Indeed, the risk per stem cell division decreases approximately linearly with
lscd, as shown in Figure 3. The unexpectedly shallow gradient of the correla-
tion between cancer risk and lscd has been noted before [12, 10] but has not, in
our view, been sufficiently investigated.
We propose that the observed relationship between cancer risk and number
of stem cell divisions can be partly explained by the saturation of cancer risk
at a maximum level substantially less than 100%. There are two (non-mutually
exclusive) reasons to expect such a saturating effect. First, different causes of
mortality (e.g., cancers, heart disease, cerebrovascular disease, accidents, etc.)
each have a characteristic probability distribution as a function of age. Be-
cause of the primacy of mortality events, increases in the probability of a given
mortality type will tend to be reflected as increased incidence as the age at
which that event occurs decreases. Thus, all else being equal, a given source of
mortality will not exceed approximately 1/N , where N is the total number of
possible attributed, independent causes of mortality. Of course, all else is not
equal, but nevertheless we would expect a saturation effect since the cancers
in T&V’s dataset tend to be life threatening at older ages (and therefore have
less primacy). Second, tissues that are especially vulnerable to life-threatening
cancers would be expected to evolve stronger means of protection [6]. That all
tissues do not employ the same protection mechanisms would be suggestive of
either a fitness cost of cancer protection to the organism (i.e. that the cost of
added protection in terms of reductions in survival and reproduction outweighs
the benefits of lowered risks of life-threatening cancer), or that the phylogenetic
emergence of tissue specific protection was somehow linked with tissue differ-
entiation during ontogeny. Therefore, for either or both hypotheses, we would
expect the gradient of the correlation between risk and lscd to become shallower
with increasing lscd, as illustrated in Figure 4.
4
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A simple model that is consistent with these assumptions is
y = − log(a+ e−x−b), (4)
where y is log(cancer risk) and x is log(lscd). For small x this function ap-
proaches y = x+ b (slope = 1), and for large x it approaches y = − log a (slope
= 0). We used a least-squares method to fit the nonlinear model to data (using
the nls function in the R statistical language [13]).
Figure 5A shows the result of fitting the above model to the data for all
31 cancer types in the T&V dataset and 3 additional neuroendocrine cancers
(small-cell lung carcinoma, and colorectal and small intestine carcinoids – see
Supplementary materials for data and sources). According to this model, most
of the types with higher than expected risk belong to subpopulations exposed
to carcinogens (hollow circles in Figure 5A). These include lung cancer in smok-
ers, intestinal cancer in those with certain inherited genetic alterations, liver
and head and neck cancer in those infected with an oncovirus, and basal cell
carcinoma, which is generally correlated with a combination of genetic factors
and UV-light exposure, and which is very rarely fatal [14].
When the risks related to specific subpopulations are omitted from the T&V
dataset, as expected, the lifetime risk per cancer type saturates at a lower level.
In the extended dataset with three additional cancer types, the saturation level
is approximately 0.5% (95% CI: 0.3-1.3%, Figure 5B). Moreover, the additional
data points (filled circles in Figure 5B) do not change the model fit. There-
fore all of the data appear to be consistent with a model in which the risk of
life-threatening cancer increases with lscd with a slope 1, until it is bounded by
a threshold of c. 0.3-1.3%; i.e., well below the theoretical maximum of 100%.
The fit of this model is statistically similar to that of the linear model (residual
standard errors 0.59 and 0.58, respectively), and, as in the preceding analysis,
s and d have independent, non-correlated statistical effects on variation in inci-
dence in the alternative dataset (p < 0.005). However, the non-linear model is
more biologically plausible, and it may therefore reveal more about the multiple
factors that determine cancer risk, including natural selection.
Variation between tissues
We have shown that tissues with higher numbers of stem cell divisions generally
have a lower risk of cancer per stem cell division. However, one would also expect
cancer risk per stem cell division to be approximately constant within sets of
related tissues, which are likely, though not certain, to have similar protection
mechanisms. By splitting the data into subsets of similar cancer types, we should
be able to divide the variation in risk into two parts (Figure 6). If the members of
each subset indeed have similar cancer risk per stem cell division then variation
within subsets will be mostly due to lscd, whereas variation between subsets
will be related to tissue type and/or environment (e.g., mutagens).
In particular, if we assume that carcinogenesis requires a sequence of M
mutations then
cancer risk ≈ s(dC)M ≈ lscd× dM−1CM , (5)
as discussed by Nunney and Muir in this issue [15]. Thus
log(cancer risk) ≈ log(lscd) + (M − 1) log(d) +M log(C). (6)
5
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If division rates d and numbers of mutations M are similar within each subset
then the ratio of risks for two cancer types is given by
log(cancer risk1)− log(cancer risk2) ≈ log(lscd1)− log(lscd2). (7)
Therefore the slope of the regression line for each subset will be approximately
1, and the cancer risk per stem cell division (that is, the risk of acquiring all
necessary mutations, relative to lscd) will be approximately the value at which
each regression line intercepts the vertical axis (i.e. log lscd = 0, Figure 6).
We hypothesized that cancer risk per stem cell division might be associated
with either anatomical site or the cell type of the transformed tissue. We first
divided the cancer types by anatomical site (Table 1 in Supplementary materi-
als), according to the topographical codes in the International Classification of
Diseases for Oncology (ICD-O) [16], which is widely used in clinical diagnosis.
We included data for three neuroendocrine cancers not considered by T&V, but
excluded six cancer types affecting particular groups (lung cancer in smokers,
intestinal cancer in those with certain inherited genetic alterations, and liver
and head and neck cancer in those infected with an oncovirus). We then fitted
a two-factor regression model to the subsets containing at least two data points
(9 subsets, 24 cancer types). According to this model, for each cancer type i,
log cancer risk(i) = A log lscd(i) +B(subset(i)), (8)
where A is the gradient of the linear regression line (assumed to be the same for
all subsets), and B is the intercept (which depends on the subset). Therefore
there are nine parameters to be estimated (one slope, and eight subset-specific
intercepts).
The two-factor regression model explains most of the variation in cancer
risk not explained by the model of T&V. For the extended dataset, the model
explains 89% of the variation in cancer risk among 24 cancer types (F9,14 = 12.7,
Figure 7A). Log lscd by itself explains 68% of the variation, similar to the
figure for the set of 31 cancer types analyzed by T&V, whereas the anatomical
subset factor explains an additional 21% (subset effect: p = 0.02). Supporting
this finding, the risks for three cancer types not considered by T&V (filled
circles in Figure 7A) are almost exactly as predicted. There is no significant
interaction between the log lscd and subset factors (p = 0.37). Furthermore the
gradient within the subsets is 0.86, with standard error 0.14, and is therefore, as
predicted, not significantly different from 1. An alternative model that assumes
the gradient for each subset is exactly 1 also explains 89% of the variation
(F8,15 = 15.9; subset effect: p < 1× 10
−5).
Note that we chose to include skin cancers in this analysis even though most
of the skin cancer risk in the T&V dataset is associated with UV-light exposure
[17]. Since UV-light exposure is assumed to increase the mutation risk per stem
cell, we would expect this environmental factor to shift the regression line for
the skin cancer subset upwards, towards higher cancer risk, but we would still
expect the slope to be approximately 1. Indeed, the model fit for skin cancer is
similar to that for the other subsets (Figure 7A).
Much of the remaining variation is due to the brain cancer subset, but it can
be argued that this subset is poorly defined. Whereas glioblastoma typically
develops in the mature brain, medulloblastoma is considered to originate in
the different environment of the early embryo [18], and it is the only cancer in
6
Page 7 of 21
http://mc.manuscriptcentral.com/issue-ptrsb
Submitted to Phil. Trans. R. Soc. B - Issue
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
the T&V dataset that predominantly occurs during childhood (median age 9
years at diagnosis). When the brain cancer subset is excluded, the two-factor
regression model explains 92% of the variation (F8,13 = 18.8) and the subset
factor has a more significant effect (p = 0.005).
Apart from brain cancers, there is only one cancer type that substantially
deviates from the topographical subsets model: although colorectal and duo-
denum adenocarcinomas lie almost exactly on a line of slope 1 (also grouping
with pancreatic cancers), small intestine adenocarcinoma falls well below this
line, being approximately ten times less common than predicted. Therefore a
testable prediction of our model is that small intestine adenocarcinoma differs
in some important way from the four other intestinal cancers (colorectal and
duodenum adenocarcinomas, and colorectal and small intestinal carcinoids), or
that the estimated lifetime number of stem cell divisions for this cancer type is
inaccurate.
We also divided the data according to ICD-O morphological code, which de-
scribes the cancer cell type. This resulted in five subsets containing at least two
data points, which together included 17 cancer types (Table 2 in Supplementary
materials). In the two-factor regression model (Equation 8), the morphological
subset factor is not significant (p = 0.32). Therefore we found no evidence that
cancer risk in this dataset is related to cell type, independent of anatomical site
(Figure 7B). Nevertheless, since topography and morphology are moderately
correlated in the T&V dataset, our results do not rule out a combined effect.
Given that the gradient of the correlation between cancer risk and lscd ap-
pears to be close to 1 for each topographical type, we can calculate
cancer risk per stem cell division = risk÷ lscd. (9)
The estimated risks per stem cell division for each individual cancer type are
shown in Figure 7C. These estimated risks vary by nearly four orders of mag-
nitude – from less than 10−14 for small intestine adenocarcinoma, to approxi-
mately 10−11 for osteocarcinoma and thyroid cancers. An untested hypothesis
to explain this variation is that the number of genetic or epigenetic alterna-
tions required to obtain cancers typical of different anatomical sites, differs in
characteristic ways (see also Nunney & Muir [15], this issue).
Therefore variation in cancer incidence in the dataset of T&V can be ex-
plained by the total number of stem divisions (lscd; [9]), but can also be under-
stood as variation explained by tissue size and by variation in cancer risk per
stem cell division (this study). When using the composite quantity lscd and
only considering cancers that are not linked to heredity, disease or mutagenic
exposure, we find that anatomical site explains most of the residual variation.
Discussion
Despite limitations in the Tomasetti and Vogelstein dataset, it contains a wealth
of information that goes beyond their initial analysis. We have made four new
findings based on their dataset, and we have verified that these findings are
consistent with additional data. First, the total number of stem cells and the
lifetime number of divisions per stem cell each significantly, and independently
of one another, explain variation in cancer incidence (Figure 1). Indeed, our
finding of a significant correlation of s with cancer risk is consistent with the
7
Page 8 of 21
http://mc.manuscriptcentral.com/issue-ptrsb
Submitted to Phil. Trans. R. Soc. B - Issue
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
prediction that cancer incidence increases with the standing population size of
an organ [19, 20]. One possible mechanism for the tissue size effect is mutations
associated with the 2s cell divisions during ontogeny for certain tissues [21].
Second, our more intuitive measure of Extra Cancer Risk yields results that
largely concord with T&V, but also yield certain notable differences (Figure 2).
Third, when assessing a subset of 27 cancers that are not primarily linked to
pathogens, disease, or carcinogenic exposure, we find a saturating effect of total
stem cell divisions on cancer incidence, with a plateau at about 0.5% (Figure 5).
This could be explained either by the primacy of mortality events limiting max-
imal mortality for any single type of event and/or increased cancer prevention
mechanisms in tissues with the most total stem cell replications. Fourth, when
dividing a subset of 24 cancers by anatomical site, we find that each type shows
the same slope of c. 1, but is displaced over 4 orders of magnitude in risk per
stem cell division, consistent with the hypothesis that different tissues have con-
trasting protection mechanisms against cancer. Data for three neuroendocrine
cancers, which were not considered by T&V, closely fit the predictions of this
model. Our findings are consistent with the hypothesis that natural selection
has resulted in differential cancer prevention in different anatomical sites [6], and
to the best of our knowledge is the first such analysis for any cellular disease.
We briefly discuss the implications of these findings below.
Our analysis clarifies one of the main findings of Tomasetti and Vogelstein
[9]: variation in cancer incidence is statistically explained by the independent
effects of stem cell division rate (d) and stem cell number (s). Our analyses
indicate, both for the full T&V dataset and for a dataset of cases that are a
priori least likely to be derived from mutagenic exposure, that both s and d
significantly contribute to explaining most of the variation in cancer incidence,
and variation explained by s and d are approximately equal in the full T&V
dataset. We hypothesize however different relative contributions of d and s to
explaining variation in risk of cancers significantly associated with mutagenic
effects (e.g., certain cancers with high ERS). Specifically, mutagenic exposure
may result in stem cell death and replacement by mutated daughter cells [22].
Thus, we predict that the incidence of mutagen-derived cancers should signif-
icantly correlate with the number of standing “targets” (s), and little or not
at all with stem cell division rates (d). We were not able to test this hypoth-
esis, not only because of the small number of cases in the T&V dataset, but
also because mutagenic exposure is likely to vary considerably both within and
between cancer types.
We have further shown that when considering the total number of stem
cell divisions as a single metric that explains most of the variation in cancer
incidence, the remaining variation can be significantly explained by anatomical
site, corresponding to the biological setting in which cancer arises. The pattern
is consistent with differential cancer risks per stem cell division, such that in
anatomical sites that harbour a relatively large number of stem cell divisions,
each division event entails a relatively low risk of contributing to carcinogenesis.
Our results therefore suggest that variation in cancer risk across human tissues
is analogous to Peto’s paradox, which is the observed lack of variation in cancer
risk across animal species with different body masses and/or lifespans [1, 2,
3, 4]. However, the inter-tissue relationship is not flat as in the interspecific
comparison, but appears to be an increasing, saturating function. Most of the
hypotheses proposed to explain Peto’s paradox invoke the evolution of stronger
8
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cellular or tissue-level cancer prevention or suppression in larger and longer-
lived animal species (reviewed in [3]). Likewise, our results are consistent with
a related conjecture of Peto [1] that tissues with high levels of stem cell turnover,
such as the lining of the small intestine, might have evolved especially powerful
anti-cancer mechanisms. For example, a larger number of mutations might be
necessary to initiate cancer in such tissues ([15], this issue), or tissue architecture
might act to contain precancerous growths [1]. Most of the cancer types in
the dataset occur at older ages and, as has been argued previously (e.g., [4]),
such cancers would be shielded from present-day natural selection. Natural
selection for cancer prevention is consistent with observations of occurrence at
post-reproductive ages, yet maintaining the evolved protection mechanisms that
reduce incidences at younger ages [23, 4]. Our analysis with an extended dataset
confirms our preliminary findings for the T&V dataset [11] and tests more recent
predictions [24].
We have shown how simple rules (effects of total number of stem cell divi-
sions and anatomical site) can predict variation in cancer incidence with high
confidence, when looking across cancer types. By extension, we speculate that
the same rules also hold across individuals: having more stem cell divisions in
a given anatomical site would then put an individual at greater risk for cancer
originating at that site. We have not investigated whether variation in the total
number of stem cell divisions between individuals is predictive of cancer risk,
but some studies are suggestive of this type of effect (e.g., [20, 25, 4, 26]). Thus,
to the extent that a given individual is potentially more prone to certain cancers
based on more expected lifetime stem cell divisions, this can be regarded as a
risk factor.
Future research should extend Tomasetti and Vogelstein’s dataset to other
tissue types and cancer types within tissues (most notably high incidence cancers
of the breast and prostate). Moreover, we need to identify possible tissue-specific
mechanisms of cancer prevention to test the hypothesis that natural selection
has influenced not only age related patterns in cancer incidence, but also tissue
specific adaptations and cancer as a possible evolutionary constraint on tissue
size [7, 8].
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Figure captions
Figure 1
Relationships between the number of stem cells per tissue (s), the lifetime num-
ber of replications per stem cell in that tissue (d) and lifetime cancer risk, across
31 cancer types (data from Table S1 in [9]). A Relationship between stem cell
replication (d) and cancer risk, after statistically correcting for the effect of stem
cell number (s). This correction was done by regressing cancer risk on s, and
then performing the partial regression of residual cancer risk on d. The r2 value
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is the square of the partial regression coefficient and quantifies the amount of
variation in residual cancer risk explained by stem cell division. B Relationship
between stem cell number (s) and cancer risk, after statistically correcting for
the effect of stem cell replication (d). The partial r2 quantifies the variation
in residual cancer risk explained by stem cell replication. C Illustration of the
combined positive effects of stem cell number (s) and stem cell replication (d) on
predicted cancer risk. Predicted values were obtained from the multiple regres-
sion of cancer risk on d and s (see text). In 0.5 log-intervals we assigned a colour
gradient to the predicted values, ranging from light orange (low predicted risk)
to dark red (high predicted risk). Thus, cancer risk increases with increasing
values of both s and d. All analyses and figures use log-transformation of s, d
and cancer risk. The black lines in A and B represent regression lines, and the
shaded areas the 95% confidence intervals around the regression. Colour-coding
based on Fig. 2 in [9], denoting deterministic D-tumours (blue) and replicative
R-tumours (green).
Figure 2
Residual lifetime risk of 31 cancer types, calculated as the difference between
observed values and predictions of our multiple regression model (Figures 1A,
1B). Most of the cancers that T&V classed as deterministic D-tumours (blue
bars) also have high residual risks according to our alternative metric. Many
such cancers are associated with known causative factors (oncoviruses, chemical
carcinogens, or inherited cancer susceptibility genes). The additional identifi-
cation of cancers with very low residual lifetime risks (red bars) suggests that
some tissue types may be differentially resistant to tumours.
Figure 3
Relationship between cancer risk per stem cell division (risk / lscd) and lifetime
number of stem cell divisions (lscd) in 31 cancer types. The negative correlation
contradicts the hypothesis that the cancer risk per stem cell division is the same
for all tissues (in which case the line would be flat, with gradient 0). Dashed lines
show 95% confidence intervals for the linear regression (R2 = 0.58, p < 1×10−6).
Figure 4
A hypothetical one-factor, non-linear model of the relationship between cancer
risk and lifetime number of stem cell divisions (lscd). If each stem cell division
has the same probability of causing cancer then there should be a linear rela-
tionship between cancer risk and lscd with a gradient of 1. However, we argue
that the risk cannot rise indefinitely, but must be bounded by a maximum limit,
either due to the primacy of other causes of mortality and/or due to differential
cancer prevention in tissues with larger total numbers of stem cell divisions.
Figure 5
A Relationship between cancer risk and lifetime number of stem cell divisions
(lscd) in 34 cancer types, described by a model that assumes that the gradient
of the correlation is 1 for small lscd, and is 0 for large lscd. Data from T&V are
12
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shown as crosses or hollow circles; additional data are shown as filled circles.
The model asymptotes are included as dashed lines. B The same model fitted
to the set of 27 cancer types not associated with a high-risk subpopulation (the
excluded data points are shown as hollow circles in A). Dotted lines indicate
the approximate 95% confidence interval of the regression curve.
Figure 6
A two-factor, linear model of the relationship between cancer risk and lifetime
number of stem cell divisions (lscd). In this case the cancer types are divided
into subsets according to tissue type. The subsetting partitions variation into
within-subset variation (due to lscd) and between-subset variation (due to tissue
type). The gradient of the correlation within subsets is expected to be close
to 1. The dashed line indicates a hypothetical maximum risk threshold. For
each tissue type, the cancer risk per stem cell division can be estimated by
extrapolating the regression line to the point where lscd = 1 (i.e. log lscd = 0).
Figure 7
A Relationship between cancer risk and lifetime number of stem cell divisions
(lscd) in nine topographically-defined subsets of 24 cancer types (Table 1 in Sup-
plementary materials). The model assumes that the risk per stem cell division
may differ between subsets but that the slope of the correlation is the same for
each subset. Data from T&V are shown as crosses; additional data are shown as
filled circles. B Relationship between cancer risk and lifetime number of stem
cell divisions (lscd) in five morphologically-defined subsets of 17 cancer types
(Table 2 in Supplementary materials). C Cancer risk per stem cell division for
28 cancer types, calculated by dividing risk by lscd. This formula assumes that
the correlation between risk and lscd has a gradient of 1 for each tissue type,
which is supported by the results of the regression model (Equation 4). Cancer
types are coloured by topographic subset, according to the scheme shown in A.
Four types that belong to topographic subsets with only one member (and so
were excluded of the analysis shown in A) are shown in grey.
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